Since RDD is a clonal histocyte disorder with mutation in the MAP2K1 and KRAS pathway (16), that are amenable to therapy with MEK inhibitors (17). This evidence concerns the gene MAP2K7 and sinus histiocytosis with massive lymphadenopathy.